Mr. Spoor was previously President, Chief Executive Officer and a member of the board of directors of Fluoropharma Medical, Inc. from February 14, 2011 until December 31, 2015. Mr. Spoor was the CFO for Sunstone BioSciences, a nanotechnology firm and as a strategy consultant at Oliver Wyman working with biotechnology, pharmaceutical, medical device and health insurance companies. Mr. Spoor was an equity research analyst at J.P. Morgan and Credit Suisse covering the biotechnology and medical device industries. Prior to his career on Wall Street, Mr. Spoor worked in the pharmaceutical industry spending 11 years with Amersham /GE Healthcare where he worked in 7 countries in a variety of commercial and strategy roles. Mr. Spoor holds a Pharmacy degree from the University of Toronto as well as an M.B.A. from Columbia University with concentrations in finance and accounting.
PhD, Chief Scientific Officer
Dr. Dupret joins after serving as President of ProteaBio Europe, a wholly-owned European subsidiary of Protea Biosciences. He joined Protea Biosciences in October 2008 to launch and manage ProteaBio Europe. Previously, Daniel founded Proteus SA in 1998 and served as its President and CEO from 1998 to 2007. He founded Appligene SA in 1985 and served as CSO, President, and CEO, respectively, until 1998. From 1982 to 1985, he served as Project Leader at Transgene SA. In parallel to his Biotechnology career, Mr. Dupret was an expert for the French government and the European commission in grant commission and funding of young biotech companies. From 2003 to 2007, he served as President of the Board of the University of Nîmes. Dr. Dupret received his PhD. at the Medical University of Strasbourg.
Chief Financial Officer
Mr. Shenouda has over 25 years of experience in the pharmaceutical and securities industries. Most recently, Mr. Shenouda was the Head of Business Development and Licensing at Retrophin, Inc. Prior to that, he served as the Head of East Coast Operations at Blueprint Life Science Group, a strategic investor relations consultancy. Mr. Shenouda spent the bulk of his career as an equity analyst with senior level positions at Stifel Nicolaus, UBS and JP Morgan, covering a broad range of small and large cap biotechnology companies. Mr. Shenouda started his sell-side career with Citigroup and Bear Stearns where his coverage universe focused on U.S and European pharmaceutical companies. Before entering Wall Street, Mr. Shenouda was a management consultant with PricewaterhouseCoopers' Pharmaceutical Consulting practice and also spent time in pharmaceutical sales, having worked as a hospital representative and managed care specialist for Abbott Laboratories' Pharmaceutical Products Division. Mr. Shenouda earned a B.S. in pharmacy from St. John's University and is a registered pharmacist in New Jersey and California. He also received an M.B.A. from Rutgers University Graduate School of Management.
MD, Chief Medical Officer
Previous to joining AzurRx, Dr. Pennington spent eleven years at Anthera Pharmaceuticals as Chief Medical Officer and Senior Clinical Fellow. Prior that, he has held senior medical positions in a number of biopharmaceutical companies, including InterMune, Cotherix, and Bayer Pharmaceutical. Dr. Pennington has led registration efforts for twelve successful BLA/NDA submissions in the U.S. and another ten in Europe and Asia. Prior to joining the biotech industry, Dr. Pennington spent ten years on the Medical Faculty of Harvard Medical School. Dr. Pennington received his medical degree from the University of Oregon Health Sciences Universary, and is boarded in internal medicine and infectious diseases.
PhD, R&D, Programs Director
Dr. Lebreton joined AzurRx in June 2015 after serving as R&D Programs Director at Eyevensys from 2013-2015. Previously he served as Therapeutic Area Leader in occular diseeases at Abbott (formerly Solvay Pharmaceuticals) from 2009-2013 and as the Global R&D Programs Director at Solvay Pharmaceuticals from 2007-2009. From 2001-2007 he held several roles at Laboratoires Fournier including Research Program Manager, Chemistry Group Leader/Senior Medicinal Chemist, and Chemistry Lab Manager from 2001-2007. Dr. Lebreton received his PhD in pharmaco-chemistry at the University of Paris VII.
PhD, Head of Laboratory
Dr. Schué joins after serving as Project Leader for the development of a new therapeutic protein (AZX1103), to be associated with antibiotics, at ProteaBio Europe since 2009. He is also involved in the API aspects (cell banking, API production and characterization) of the MS1819 pharmaceutical development. Dr. Schué graduated first as a chemical engineer at “Ecole Nationale Supérieure de Chimie de Montpellier” (ENSCM), Montpellier with specialization in biochemistry and molecular biology and then with a PhD in molecular microbiology at the University of Birmingham, UK. With three years of post-doctoral positions at “Commissariat à l’Energie Atomique” (CEA) at Cadarache, and CNRS, Marseille, he has gained solid expertise in biotechnology (recombinant protein expression and purification) and enzymology (molecular and structural characterizations). Dr. Schué received his Ph.D. in molecular microbiology at the University of Birmingham in the UK.
Vice President for Finance and Business Development
Mr. Krusin is an experienced executive with 20 years of business development, strategic marketing, financing and operating experience in the healthcare, financial services, and consulting sectors. Prior to joining AzurRx BioPharma as VP for Business Development in 2014, Mr. Krusin was VP for BD at FluoroPharma Medical, Inc.; Director of Business Development at Clewed (a business services and investment partnership); an Experienced Commercial Leader at GE Capital in its Global Sponsor Finance, Healthcare Financial Services, and Capital Solutions units; Vice President of Marketing & Sales and Director of Business Development at Electro-Optical Sciences (now MelaSciences); and an analyst in the Emerging Markets Strategic Planning Group at Citigroup. Mr. Krusin received a MBA from Columbia Business School in finance and marketing, a MPhil. in political economy from Oxford University, and a BA in international relations from Swarthmore College.
PhD, Vice President for Translational Research
Dr. Srinivasan has over 15 years of leadership experience in drug discovery and development in the pharmaceutical industry. He previously was Director, Scientific BD at Anthera Pharmaceuticals Inc., where he wore multiple hats including program management and translational sciences to support the ongoing clinical development programs. He began his career in industry as a post-doctoral fellow at Roche Palo Alto and worked in drug discovery as Scientist/Senior Scientist/Group Leader at Roche in Palo Alto and Nutley, NJ. Dr. Srinivasan received his MSc in Biotechnology from The University of Mumbai, India and a PhD In Pharmacology & Toxicology from the University of Arizona, Tucson.
Vice President for Clinical Operations
Ms. Gangal is an experienced clinical operations executive with over 12 years of experience in leading clinical trials across small and large biotech and joined AzurRx in July 2018. She has extensive experience in leading and executing late phase trials with a specialization in global trials having led clinical studies in over 25 different geographies. She has led numerous trials across the cystic fibrosis community. Monica holds a Masters of Biotechnology from the University of Toronto and a Bachelors in Biochemistry and Chemical Engineering from the University of Ottawa.